Efficacy of Remibrutinib versus Dupilumab at Early Timepoints in Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM).

Dermatol Ther (Heidelb) · 2026 · PMC13219691 · PMID 41854973

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

However, in LIBERTY-CSU CUPID study B, which included patients with CSU who were intolerant or incomplete responders to omalizumab, although a numerical trend was observed, the primary endpoint of change from baseline in ISS7 at week 24 was not met [ 19 ].

also in 723 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.